Clinical trial
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic…
NCT00023998 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00023998 |
|---|---|
| Title | Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma |
| Official title | A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Osteosarcoma |
| Intervention type | Biological, Drug, Other, Procedure, Radiation |
| Interventions | doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab and 1 more |
| Enrollment | 80 |
| Start date | Jul 1, 2001 |
| Primary completion | Nov 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: